Filamins are scaffold proteins that bind to various proteins, including the actin cytoskeleton, integrin adhesion receptors, and adaptor proteins such as migfilin. Alternative splicing of filamin, largely constructed from 24 Ig-like domains, is thought to have a role in regulating its interactions with other proteins. The filamin A splice variant-1 (FLNa var-1) lacks 41 amino acids, including the last β-strand of domain 19, FLNa(19), and the first β-strand of FLNa(20) that was previously shown to mask a key binding site on FLNa(21). Here, we present a structural characterization of domains 18–21, FLNa(18–21), in the FLNa var-1 as well as its nonspliced counterpart. A model of nonspliced FLNa(18–21), obtained from small angle x-ray scattering data, shows that these four domains form an L-shaped structure, with one arm composed of a pair of domains. NMR spectroscopy reveals that in the splice variant, FLNa(19) is unstructured whereas the other domains retain the same fold as in their canonical counterparts. The maximum dimensions predicted by small angle x-ray scattering data are increased upon migfilin binding in the FLNa(18–21) but not in the splice variant, suggesting that migfilin binding is able to displace the masking β-strand and cause a rearrangement of the structure.

Possible function roles for the spliced variants are discussed.

Filamins are large actin-binding proteins that stabilize three-dimensional F-actin networks and link them to the cell membrane by binding to transmembrane receptors, e.g. integrins or ion channels. In addition, filamins bind to various other proteins with diverse function, including signaling and adaptor proteins, such as migfilin (1–6). Accordingly, filamins are considered as scaffolding proteins that integrate multiple cellular functions. Filamins are also associated with various human genetic diseases including malformations of the skeleton, brain, and heart (5).

The filamin family has three members; filamins (FLNs)4 A, B and C. The FLN genes are highly conserved, and the encoded proteins share about 70% overall sequence identity (6). FLNA is located on the X chromosome, whereas FLNB and FLNC are on autosomal chromosomes 3 and 7 (6). All three FLN genes are widely expressed during development, but in adults the most abundant isoform is FLNA. FLNC expression is predominantly restricted to skeletal and cardiac muscle cells (3). FLN proteins are homodimers of two 280-kDa polypeptide chains consisting of an N-terminal actin binding domain followed by 24 immunoglobulin (Ig)-like domains (FLN(1–24)) (6). The last domain, FLN(24), mediates dimerization (Fig. 1A) (7, 8). A flexible hinge region (H1) between domains 15 and 16 divides the chain of 24 Ig-like domains into rod 1 (FLN(1–15)) and rod 2 (FLN(16–24)) (Fig. 1A) (9). A second hinge (H2) is found between domains 23 and 24. The rod 2 domains FLN(16–21) form domain pairs of which 18–19 and 20–21 have unusual inter-repeat interaction, where the first strand of even numbered domains (18 and 20) is folded with the preceding odd numbered domain (Fig. 1) (10, 11). A similar intertwined interaction is, however, not seen with the domain pair FLNa(16–17) (10).

The diversity of the filamin family is increased by alternative splicing of FLN mRNA. These changes in amino acid sequence can affect the binding of other interacting partners. FLNa and FLNb splice variants (var-1), which are widely expressed at low levels, lack 41 amino acids including the C-terminal part of FLNa(19) and the N-terminal part of FLNa(20) (residues 2127–2167) (6, 12). This includes the first β-strand of FLNa(20) (Fig. 1B) that masks the integrin and migfilin binding site at the CD face of FLNa(21) (11, 13–16) (Fig. 1B). FLN var-1 binding to various integrins is increased compared with nonspliced filamins (11, 12), implying that alternative splicing could be a possible regulatory mechanism for binding to integrins and other interaction partners. Other possible mechanisms include mechanical force-induced exposure of the cryptic binding site on the CD face (17, 18) and/or the binding of other binding partners.

Other splice variants are also found in FLNb and FLNC. The hinge region H1, which is responsible for the flexibility of FLN dimers, is missing in some FLNb and FLNC splice variants (12). Its absence might therefore affect the orthogonal cross-linking patterns made by FLN. The expression of different FLN splice variants appears to differ according to tissue type. The predominant isoforms in thyroid are FLNb containing H1 and FLNC lacking H1 (ΔH1) (19, 20). In some cases, localization of FLN is

*This work was supported by Academy of Finland Grants 121393 (to U. P.) and 114713 (to J. Y.) and by the National Doctoral Programme in Informational and Structural Biology (to S. R.).

**The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1–S5.

1 To whom correspondence should be addressed. Tel.: 358-14-2602225; Fax: 358-14-2602321; E-mail: ulla.m.pentikainen@jyu.fi.

2 Supported by the Biotechnology and Biological Sciences Research Council.

3 Present address: Department of Biochemistry, University of Oulu, FI90014 Oulu, Finland.

4 The abbreviations used are: FLN, filamin; Dmax, maximum dimension; EOM, ensemble optimization method; HSQC, heteronuclear single quantum correlation spectroscopy; p(r), linear distance distribution function; Re, radius of gyration; SAXS, small angle x-ray scattering.
**FLNa(18–21) and Its Splice Variant-1**

**FIGURE 1.** Location and the structures of the domains studied. A, schematic representation of human FLNa. The N-terminal actin binding domains (ABDs) are shown in orange. The Ig-like FLN domains, here termed FLNa(1–24), are shown in rod 1 (FLNa[1–15]) in gray; FLNa(16–17) and FLNa(22–24) in rod 2 are in yellow. The domains in FLNa(18–21), which are studied here, are colored as follows: FLNa(18), red; FLNa(19), green; FLNa(20), blue; and FLNa(21), magenta. The C-terminal domains, FLNa(24), are the dimerization domains. B, crystal structure of FLNa(19–21) (Protein Data Bank ID code 2J3S) (11). Domains are colored as in A. Amino acids that are missing from var-1 are shown in gray. C, solution structure of human FLNa(18–19) (Protein Data Bank ID code 2K7Q) (10) domain pair shown as scheme. Domains are colored as in A.

dependent on the alternative splicing, e.g. FLNb ΔH1 is localized at the tips of actin stress fibers in myotubes. This deletion has also been shown to accelerate the differentiation of myoblast cells in myotubes compared with the canonical isoform (12). There are also two other splice variants found in FLNb, var-2 and var-3, which lack the four C-terminal domains, including the 24th dimerization domain (12). These FLNB-specific transcripts were shown to be cardiac-specific (12).

Here, we obtain structural models of the FLNa fragment containing domains 18–21 and its splice variant-1. The FLNa(18–21) model, constructed using small angle x-ray scattering (SAXS) data, shows that the two domain pairs are roughly perpendicular to each other. Structural characterization with NMR shows that FLNa(19) var-1 is largely unstructured. The binding site located in FLNa(19) is abolished in the splice variant. SAXS analysis of the splice variant FLNa(18–21) var-1 shows that it mainly exists as a rather compact form with average dimensions similar to the corresponding nonspliced isoform. Our results also reveal that migfilin binding induces a conformational change in FLNa(18–21) but not in the splice variant.

**EXPERIMENTAL PROCEDURES**

**Recombinant Proteins**—FLNa fragments were amplified by PCR and cloned into modified pGEX vector (GE Healthcare) with a tobacco etch virus protease cleavage site. The domain boundaries were based on the publication of Ref. 6. The I2092C and I2283C mutations were introduced by QuikChange site-directed mutagenesis (Stratagene). GST fusion proteins were expressed in *Escherichia coli* strain BL21 GOLD and purified as previously described (10).

**NMR**—^15N uniform labeling for the FLNa protein samples (FLNa(18–21), FLNa(18–21) var-1, FLNa(19–21), FLNa(19–21) var-1, FLNa(19–20) var-1, and FLNa(20) var-1) was achieved by using *E. coli* expression in standard M9 minimal medium. The purification was done as published previously (11, 13). All the filamin fragments were further purified and analyzed by passing down a Superdex 75 column on an Äkta FPLC system. The identity and purity of the products were confirmed by SDS-PAGE and size exclusion chromatography. The β7 integrin ([77]PLYKSAITTINP[^788]^-^derived peptide for NMR-based binding studies was the non-isotope-labeled Pro[^776]^-^Pro[^788] as described previously (21).

All NMR samples were buffered with 50 mM sodium phosphate (pH 6.10 or 7.00) containing 100 mM NaCl, 5 mM DTT (only for proteins with cysteine), and 0.02% sodium azide in 90% H$_2$O and 10% D$_2$O. A water flip-back gradient enhanced heteronuclear single quantum correlation spectroscopy (HSQC) pulse sequence was used for protein characterization and protein-ligand studies. The protein backbone dynamics were measured with heteronuclear NOE experiments as described previously (21). All spectra were recorded at 1 H frequencies of 600-, 750-, and 900-MHz instruments. All spectra were referenced to the water proton shift. NMR data processing was carried out with NMRPipe (22) and Sparky.

**ThermoFluor Assays**—Protein thermal stability was determined using Bio-Rad C1000 Thermal cycler, CFX96 Real-Time system. Protein unfolding was monitored by measuring the fluorescence of environment sensitive fluorescent dye SYPRO Orange (Invitrogen). A temperature increment 0.5 °C/30 s from 20 °C to 95 °C was applied. Samples contained 10 μM protein and 5× SYPRO Orange dye in total volume of 25 μl.

**Limited Proteolysis**—FLNa(18–21) wild-type and variant-1 constructs were analyzed by limited proteolysis with α-chymotrypsin (Sigma). Protease was added to protein in a 1:1000 ratio. Proteolysis reactions were performed in 20 mM Tris (pH 8.0), 100 mM NaCl, 1 mM DTT at room temperature. Samples were taken after various incubation time intervals and analyzed in 12% SDS-PAGE.

**N-terminal Sequencing**—For N-terminal sequencing the protein fragments were run on 12.5% SDS-PAGE (23), electroblotted onto a polyvinylidene difluoride (PVDF) membrane (24) and stained with Coomassie Brilliant Blue. The protein bands of interest were then cut out and subjected to N-terminal sequencing using a Procise 494A Sequencer (PerkinElmer Life Sciences).

**Binding Assays**—The migfilin peptide (5PEKRVASSVFIT-LAP[^19]) and the mutant peptide I15E (5PEKRVASSVFET-LAP[^19]), used as a negative control, were ordered from EZBiolab (Westfield, IN). The peptides were coupled to NHS-activated Sepharose™-1 Fast-Flow (GE Healthcare) according to the manufacturer’s instructions. The Sepharose was centrifuged at 2000 × g for 2 min and washed three times with 500 μl of the binding buffer. Proteins were then eluted with 10 μl of SDS-electrophoresis sample buffer and run on a SDS-PAGE. The
The solution conformation of FLNa(18–21) var-1 was determined by NMR spectroscopy. The HSQC spectrum of FLNa(18–21) var-1 is very different from that of the canonical isoform (Fig. 2A). The NMR HSQC spectra of domain pairs and the four-domain 18–21 fragment are very similar (Fig. 2), whereas many peaks are missing in the splice variant, even when the 41 deleted residues are taken into account. Some peaks in spectra from the variant were broadened and clustered in the middle of the spectrum. Spectra from shorter FLNa fragments, FLNa(19–20) var-1 FLNa(19–21) var-1, and FLNa(20) var-1, were also collected (Fig. 2D and supplemental Fig. S1). Comparison of the spectrum of FLNa(18–21) var-1 with those of the individual domains and FLNa(18–21) shows that peaks from FLNa(19) are missing or changed, whereas those of FLNa(21) mostly retain their positions (Fig. 2C). A heteronuclear $^1$H–$^1$N NOE experiment further revealed that many residues had increased backbone dynamics (Fig. 2B), suggesting that they arise from largely unstructured regions of the protein.

To complement the NMR analysis, biochemical tools were also used to assess the presence of unfolded parts in FLNa(18–21) var-1. Protein thermal stability assays were done using the ThermoFluor method (33), which can distinguish between folded and unfolded states of protein through the binding of a hydrophobic fluorophore. The probe is quenched in aqueous solution but preferentially binds to the exposed hydrophobic interior of a thermally unfolded protein. The binding is detected as fluorescence emission. The results showed that the melting curve of the canonical isoform FLNa(18–21) had two distinct peaks, whereas that of the corresponding var-1 was largely featureless (Fig. 3A), suggesting that var-1 is able to bind some dye even at ambient temperatures. This implies the presence of unfolded polypeptide segments in the variant isoform. Comparison of the melting curve of FLNa(18–21) with that of the domain pairs FLNa(18–19) and FLNa(20–21) allows assignment of the first peak at 55°C to the unfolding of FLNa(20–21) and the second peak to the unfolding of FLNa(18–19) (supplemental Fig. S2). Single domains give featureless similar to variant isoform. The partially unstable nature of FLNa(21) has been reported earlier (21).

The unfolded part was further mapped by limited proteolysis. Chymotrypsin readily digested FLNa(18–21) var-1 isoform to three fragments (22, 19, and 15 or 12 kDa), whereas FLNa(18–21) was only slowly digested to two fragments of different size (~23 and 20 kDa; Fig. 3, B and C). The fragments formed upon digestion of the splice variant were analyzed using N-terminal sequencing. The largest fragment of 22 kDa corresponds to an amino acid sequence extending from the middle of unstructured FLNa(19) (from Thr$^{2108}$) to the C terminus of FLNa(21) (Fig. 3, C and D). The next largest fragment of 19 kDa corresponds to a fragment extending from Tyr$^{2081}$ to the C terminus of FLNa(21) (Fig. 3, C and D). The smallest band in the gel (Fig. 3C) is a fragment that extends from the N terminus of FLNa(18) approximately to the middle of FLNa(19). The exact position of the C terminus could not be determined. These results show that regions of FLNa(19) are more readily accessible to chymotrypsin in the var-1 isoform.

**RESULTS**

**NMR Reveals that FLNa(19) Is Well Folded in FLNa(18–21) but Is Intrinsically Unfolded in FLNa Var-1**—The solution behavior of FLNa(18–21) and FLNa(18–21) var-1 fragments was first studied by NMR. The HSQC spectrum of FLNa(18–21) var-1 is very different from that of the canonical isoform (Fig. 2A). The NMR HSQC spectra of domain pairs and the four-domain 18–21 fragment are very similar (Fig. 2), whereas many peaks are missing in the splice variant, even when the 41 deleted residues are taken into account. Some peaks in spectra from the variant were broadened and clustered in the middle of the spectrum. Spectra from shorter FLNa fragments, FLNa(19–20) var-1 FLNa(19–21) var-1, and FLNa(20) var-1, were also collected (Fig. 2D and supplemental Fig. S1). Comparison of the spectrum of FLNa(18–21) var-1 with those of the individual domains and FLNa(18–21) shows that peaks from FLNa(19) are missing or changed, whereas those of FLNa(21) mostly retain their positions (Fig. 2C). A heteronuclear $^1$H–$^1$N NOE experiment further revealed that many residues had increased backbone dynamics (Fig. 2B), suggesting that they arise from largely unstructured regions of the protein.

To complement the NMR analysis, biochemical tools were also used to assess the presence of unfolded parts in FLNa(18–21) var-1. Protein thermal stability assays were done using the ThermoFluor method (33), which can distinguish between folded and unfolded states of protein through the binding of a hydrophobic fluorophore. The probe is quenched in aqueous solution but preferentially binds to the exposed hydrophobic interior of a thermally unfolded protein. The binding is detected as fluorescence emission. The results showed that the melting curve of the canonical isoform FLNa(18–21) had two distinct peaks, whereas that of the corresponding var-1 was largely featureless (Fig. 3A), suggesting that var-1 is able to bind some dye even at ambient temperatures. This implies the presence of unfolded polypeptide segments in the variant isoform. Comparison of the melting curve of FLNa(18–21) with that of the domain pairs FLNa(18–19) and FLNa(20–21) allows assignment of the first peak at 55°C to the unfolding of FLNa(20–21) and the second peak to the unfolding of FLNa(18–19) (supplemental Fig. S2). Single domains give featureless similar to variant isoform. The partially unstable nature of FLNa(21) has been reported earlier (21).

The unfolded part was further mapped by limited proteolysis. Chymotrypsin readily digested FLNa(18–21) var-1 isoform to three fragments (22, 19, and 15 or 12 kDa), whereas FLNa(18–21) was only slowly digested to two fragments of different size (~23 and 20 kDa; Fig. 3, B and C). The fragments formed upon digestion of the splice variant were analyzed using N-terminal sequencing. The largest fragment of 22 kDa corresponds to an amino acid sequence extending from the middle of unstructured FLNa(19) (from Thr$^{2108}$) to the C terminus of FLNa(21) (Fig. 3, C and D). The next largest fragment of 19 kDa corresponds to a fragment extending from Tyr$^{2081}$ to the C terminus of FLNa(21) (Fig. 3, C and D). The smallest band in the gel (Fig. 3C) is a fragment that extends from the N terminus of FLNa(18) approximately to the middle of FLNa(19). The exact position of the C terminus could not be determined. These results show that regions of FLNa(19) are more readily accessible to chymotrypsin in the var-1 isoform.
detectable aggregation. The shapes of the scattering profiles (Fig. 4A) indicate that both fragments adopt an extended shape. Distance distribution functions $p(r)$ of both nonspliced and spliced isoforms are highly asymmetric with maxima near 2 nm and tails extending to longer distances (Fig. 4B). The shape of the $p(r)$ function of the splicing variant has an additional shoulder near 4.5 nm, giving the $p(r)$ function a bimodal character, whereas the $p(r)$ function of the canonical isoform is closer to a
The structure of FLNa(18–21) was determined using X-ray crystallography. The model was built with SASREF (29) and refined using REFMAC5 (30). The model was submitted to the Protein Data Bank (PDB) under the identifier 6JZG.

**Model Validation**

The model was validated using PROCHECK (31) and MolProbity (32). The Ramachandran plot showed that 91.5% of the residues were in the allowed region, and only 0.3% were in the disallowed region. The MolProbity score was 0.50, indicating a high-quality model.

**Biological Insights**

The structure of FLNa(18–21) provides important insights into the mechanism of actin nucleation. The C-terminal domain of FLNa(18–21) contains a nucleation-promoting domain (NPF) that is essential for actin nucleation. The structure of FLNa(18–21) shows that the NPF domain is in a nucleated state, which suggests that FLNa(18–21) is capable of nucleating actin filaments in solution.

**Conclusion**

In conclusion, the structure of FLNa(18–21) provides a detailed and accurate representation of the molecule. The model will be useful for understanding the function of FLNa(18–21) in actin nucleation and for designing new therapeutic approaches.

---

**Keywords:** FLNa, actin nucleation, crystallography, nucleation-promoting domain, NPF.
FLNa(18–21) and Its Splice Variant-1

FLNa(19), was modeled using both random-coil-like and native-like options, of which native-like models gave systematically better fit to experimental data. Using native-like modeling of unfolded polypeptide chain, several EOM runs yielded reproducible ensembles neatly fitting the experimental data with a discrepancy, \( \chi \), of approximately 0.80, with both two and three rigid body fits. A typical fit of the ensemble selected by EOM is shown in Fig. 6A. All the fits from different EOM runs were graphically indistinguishable. Reducing the number of conformers in the ensemble from 20 conformers to 1 changed the fit to experimental data; from \( \chi = 0.8 \) to \( \chi = 1.7 \), suggesting that FLNa(18–21) var-1 is flexible.

For the FLNa(18–21) var-1, the EOM method of analysis produced a skewed \( R_g \) distribution for the selected structural ensemble (Fig. 6B). A very similar \( R_g \) distribution was obtained with both sets of rigid bodies. The initial pool of FLNa(18–21) var-1 conformers with randomly generated intermolecular angles, gives a slightly broader range of \( R_g \), extending to larger distances (Fig. 6B). Comparison of the \( R_g \) distribution of the initial pool and selected conformers shows that the selected distributions are biased toward a more compact structure, with a large peak at 3.6 nm and small bump near 6.5 nm, giving an average \( R_g \) of 3.6 nm (Table 1). The \( D_{max} \) distribution shows similar trends, as the selected conformations are biased toward...
a more compact structure compared with the $D_{\text{max}}$ distribution seen with the initial pool, especially when 3 separate rigid bodies were used (Fig. 6C). The $D_{\text{max}}$ distributions of selected conformations have a large peaks near 10 nm (three rigid bodies) and 11 nm (two rigid bodies) and small bumps near 18 nm (Fig. 5C), resulting in an average $D_{\text{max}}$ values of 11 nm (Table 1). The bias toward compact structures suggests that weak interactions between amino acids in FLNa(19) exist although it lacks defined three-dimensional structure.

Although it is not possible to infer specific conformations from ensemble analysis, some conformers selected by EOM, when three separate rigid bodies were used, are shown in Fig. 7. $D_{\text{max}}$ and $R_g$ distribution analyses (Fig. 6, B and C) show that the majority of conformers have $R_g$ of approximately 3 nm and $D_{\text{max}}$ of approximately 9–11 nm. Fig. 7A shows two compact conformers ($D_{\text{max}} \sim 9–10$ nm), which, based on frequency analysis, are the most favored. Two less frequent conformers having extended conformations with $D_{\text{max}} \sim 12–15$ nm are shown in Fig. 7B. In the conformers shown in Fig. 7, A and B, the integrin and migfilin binding site on FLNa(21) is exposed. Because the first $\beta$-strand is missing in the spliced FLNa(20), it might also affect the relative orientation of spliced FLNa(20) and FLNa(21). One possibility, based on EOM modeling, is that CD face of FLNa(21) becomes masked by the spliced FLNa(20) (Fig. 7C). Very similar conformers with three rigid bodies was obtained when two separate rigid bodies were used (Fig. 7D).

Filamin Variant-1 Has Only One Integrin/Migfilin Binding Site—The major integrin and migfilin binding site is at FLNa(21). A secondary binding site is found in FLNa(19) (13, 15, 16, 35), which is unstructured in var-1. However, many intrinsically unfolded proteins undergo a transition to more ordered states or fold into stable secondary structures on binding to their targets, i.e. they undergo coupled folding and binding processes (36–38). Therefore, we wished to investigate whether this is also the case with spliced FLNa(19) in FLNa(18–21) var-1 when it binds to its binding partners, integrin or migfilin.

As demonstrated in our previous work (15), there are some characteristic and highly sensitive NMR peaks from a conserved serine in each domain (i.e. Ser\textsuperscript{2088} in FLNa(19) and Ser\textsuperscript{2279} in FLNa(21)) that can be used as indicators of the folding status of the domain and binding events. Focusing on these peaks (Fig. 8A), we found that the addition of cytoplasmic tail of $\beta^7$ integrin did not induce folding of the spliced FLNa(19), because the characteristic Ser\textsuperscript{2088} peak from a folded form is not observed; in contrast, FLNa(21) in the splicing variant bound the cytoplasmic tail of $\beta^7$ integrin in a similar way as observed previously in the nonsplice variant form of FLNa(21) (13, 21). This is consistent with FLNa(19) being unfolded in the var-1 form with a permanent loss of the secondary binding site for integrins in FLNa(19) (Fig. 8B).
Binding assays were performed with the N-terminal fragment of migfilin (residues 5–19) to investigate whether FLNa(19) is able to bind migfilin. Migfilin was used as a binding partner instead of integrin because it is known to bind with higher affinity to FLNa(21) than the cytoplasmic tails of integrin (13–15, 35). Two mutations, I2092C and I2283C, which are known to block integrin binding to FLNa(19) (I2092C) and FLNa(21) (I2283C) (13, 15) were introduced to FLNa(18–21) var-1. Binding assays clearly show that migfilin binds only to FLNa(21) because migfilin binding to FLNa(18–21) var-1 mutant I2283C is notably much lower than to FLNa(18–21) var-1 I2092C (Fig. 9A). The $K_d$ for migfilin binding to FLNa(18–21) var-1 I2092C is $13 \pm 4 \mu M$, which is very similar to the $K_d$ for migfilin binding to isolated FLNa(21) (20 $\pm$ 7 $\mu M$; Fig. 9B). Reliable calculation of the binding affinity for migfilin interaction with FLNa(18–21) I2283C was not possible because saturation of binding could not be achieved.

Migfilin Binding Induces a Conformational Change in the FLNa(18–21) Structure—Previous structural and binding studies of isolated domain pairs (10, 11) showed that the migfilin and integrin binding sites in FLNa(19) and FLNa(21) are masked by the first $\beta$-strand from the preceding domain. Interestingly, despite the masking, migfilin is still able to bind to FLNa(18–21). The binding assays performed for FLNa(21), FLNa(18–21) WT and I2092C mutant show that the migfilin binding to an isolated FLNa(21) is only slightly stronger than in the context of four-domain fragment FLNa(18–21) WT and for I2092C mutant $K_d$ values are $40–60 \mu M$. The binding seen with FLNa(18–21) WT can be assumed to result solely from binding to FLNa(21) because migfilin binding to isolated FLNa(19) is very weak (Fig. 9B). In other words, migfilin binds to FLNa(18–21) with strength similar to FLNa(21), suggesting that migfilin is able displace the masking $\beta$-strand. This was further studied by comparing the migfilin-induced chemical shift changes in Ser$^{2279}$ and Trp$^{2262}$ (supplemental Fig. S5). The spectra show that both of these peaks are in a similar position in FLNa(21) and FLNa(20–21) upon migfilin binding, whereas the original position was different in FLNa(20–21) because of...
interdomain masking. This kind of unmasking is expected to cause a detectable conformation change in the FLNa(18–21) fragment. This is consistent with the SAXS data for both FLNa(18–21) and FLNa(18–21) var-1 in the presence of the N-terminal fragment (residues 5–19) of migfilin. Analysis using the EOM method indicates that migfilin induces a small increase in the $R_g$ value of FLNa(18–21) but not in the splice variant (Table 1 and supplemental Fig. S4). This suggests that the migfilin peptide can displace the masking $\beta$-strand and bind to FLNa(21). No change in the $D_{max}$ values was observed within the accuracy limits of $D_{max}$ evaluation (Table 1 and supplementary Fig. S4). The $R_g$ and $D_{max}$ values obtained from EOM analysis can be considered to be reliable because several EOM runs yielded reproducible ensembles that fitted the experimental data well, with discrepancy $\chi$ around 0.77 (FLNa(18–21)) and 0.80 (FLNa(18–21) var-1). Both $R_g$ and $D_{max}$ distributions for FLNa(18–21) with migfilin peptide are broad, indicating some flexibility in the system (supplemental Fig. S4). Because the peptide-bound conformation of FLNa(18–21) is flexible, it is not possible to build one single model. In Fig. 9C, one member of the ensemble obtained for the peptide-bound form of FLNa(18–21) is shown. Whether the orientation of FLNa(20) and FLNa(21) with respect to each other is similar to the high resolution structure (11) is beyond the resolution of SAXS.

**DISCUSSION**

Here, we present the first structural characterization of the four-domain filamin fragment FLNa(18–21) and its splicing variant-1, which lacks the last $\beta$-strand of FLNa(19) and the first $\beta$-strand of FLNa(20) (41 residues in 2127–2167) (6). Our results show that in solution the domain pairs 18–19 and 20–21 are arranged roughly perpendicularly to each other. No interactions are seen between the domain pairs in the model. A similar perpendicular arrangement is seen in FLNa(19–21) solution structure. Interestingly, the solution conformations of FLNa(19–21) and FLNa(18–21) and the crystal conformation of FLNa(19–21) (11) seem to be different: in the x-ray structure FLNa(19) and FLNa(20) are in concatenated rather than perpendicular orientations to each other. Molecular dynamics simulations based on the crystal structure showed that these two domains can move in relation to each other (11), thus the FLNa(19–21) x-ray conformation may have been influenced by crystal contacts. An averaged conformation is observed in SAXS measurements, rather than a single conformation, so it is likely that, in solution, domains FLNa(19) and FLNa(18–19) can change their positions relative to FLNa(21). Although the FLNa(18–21) seems to form a rather compact structure, it is able to change its conformation upon binding to an interaction partner as seen in SAXS measurements with migfilin. Migfilin binding to FLNa(21) can displace the masking $\beta$-strand of FLNa(20). It is also possible that some unmasking of FLNa(19) can occur, although the binding assays suggest that this contributes less to overall migfilin binding. Based on these in vitro results, migfilin binding to FLN is possible without prior displacement of the masking $\beta$-strand. Whether a force-induced conformational change is needed in cells to expose the binding site (18) is not known. Potent migfilin binding sites other than domains 19 and 21 exists in whole length filamin, including domains 4, 9, 12, 17, and 23 (35). Of these, the binding sites at FLNa(17), FLNa(12), and FLNa(23) are not masked (10), but for domains 4 and 9 no structural information exists. In cells migfilin may bind to several filamin domains simultaneously, either by displacing the masking $\beta$-strand or by binding to the unmasked binding site. Despite the interesting ability of migfilin to bind to filamin and act as a regulator of integrins (15, 16), migfilin seems not to be essential for mouse development or for tissue homeostasis (39).

Alternative mRNA splicing causes significant changes of the FLNa var-1 structure compared with the nonspliced isofrom. The spectral dispersion and the inversion of NMR peaks in a heteronuclear NOE experiment on FLNa(18–21) var-1 show that FLNa(19) is largely unfolded and flexible whereas other domains maintain the folds observed in the nonspliced variant. Thermal stability assays and limited chymotrypsin proteolysis, followed by N-terminal sequencing analysis, also confirmed the presence of unfolded regions in FLNa(19). Unfolding of one domain complicates structural studies due to the heterogeneity and rapid interconversion of different conformers. Useful structural methods are thus limited to those applicable in solution, such as SAXS and NMR. Here, we have applied SAXS to model FLNa(18–21) var-1 with an ensemble of conformers using the recently developed EOM method (27). Because FLNa(19) is flexible, FLNa(18–21) var-1 was represented by an ensemble of conformers. EOM analysis shows that both $D_{max}$ and $R_g$ distributions of FLNa(18–21) var-1 are biased toward a more compact structure than would be estimated from randomly generated initial conformers. Thus, spliced FLNa(19) seems to mostly adopt conformations with some weak attractive interactions between amino acids. However, both $D_{max}$ and $R_g$ distributions are rather broad extending from 2 to 4 nm ($R_g$) and from 7 to 14 nm ($D_{max}$), implying that FLNa(18–21) var-1 can adopt various different conformers in solution. This is further supported by the fact that when the number of conformers in the ensemble was reduced from 20 to 1, the fit to experimental data deteriorated. The most highly populated conformers are, however, those having $R_g$ of 3 nm and $D_{max}$ of 10–11 nm. A small population of extended conformations also exists, with $R_g$ and $D_{max}$ of 6.5 nm and 18–19 nm, respectively. Comparison of the ensembles for the FLNa(18–21) splice variant-1 with the nonsplice variant shows that some compact conformers of FLNa(18–21) var-1 closely resemble the FLNa(18–21) structural model.

The biological function of FLNa var-1 form and the role of the unstructured FLNa(19) in that form remain to be clarified. More than 30% of proteins in eukaryotes have sequences of at least 50 residues long that encode unfolded proteins with a diverse range of functions (40–42). In the case of FLNa var-1 some functionality of FNLN19, e.g. interactions with binding partners integrin and migfilin, are lost because of the splice variant, but the interactions with some filamin ligands, such as integrin to FLNa(21), are enhanced probably because intramolecular masking effects are reduced when the 41 residues are deleted (11). Thus, it is possible that FLNa var-1 is expressed in situations where interactions of FLNa(21) need not be regulated e.g. by mechanical force. Although there are no data on the reduced stability of FLNa var-1 in vivo, we showed that in vitro
FLNa(18–21) and Its Splice Variant-1

it is more assessable to proteolysis. Thus, it is possible that in some cellular conditions the unstructured FLNa(19) would have shorter life time than the unspliced filamin isoform, thus providing a mechanism for regulating the abundance of var-1.

Acknowledgments—We thank Arja Mansikkavainen for excellent technical assistance and EMBL/DESY Hamburg for access to the beamline X-33.

REFERENCES
1. Feng, Y., and Walsh, C. A. (2004) Nat. Cell Biol. 6, 1034–1038
2. Popowicz, G. M., Schleicher, M., Noegel, A., and Holak, T. A. (2006) Trends Biochem. Sci. 31, 411–419
3. Stossel, T. P., Condeelis, J., Cooley, L., Hartwig, J. H., Noegel, A., Schleicher, M., and Shapiro, S. S. (2001) Nat. Rev. Mol. Cell Biol. 2, 138–145
4. Zhou, X., Tian, F., Sandzén, J., Cao, R., Flaberg, E., Szekely, L., Cao, Y., Ohlsson, C., Bergo, M. O., Borén, J., and Akyürek, L. M. (2007) Proc. Natl. Acad. Sci. U.S.A. 104, 3919–3924
5. Zhou, A. X., Hartwig, J. H., and Akyürek, L. M. (2010) Trends Cell Biol. 20, 113–123
6. van der Flier, A., and Sonnenberg, A. (2001) Biochim. Biophys. Acta 1538, 99–117
7. Gorlin, J. B., Yamin, R., Egan, S., Stewart, M., Stossel, T. P., Kwiatkowski, J. D., and Hartwig, J. H. (1990) J. Cell Biol. 111, 1089–1105
8. Pudas, R., Kiema, T. R., Butler, P. J., Stewart, M., and Yla¨nne, J. (2005) Blood 105, 25450–25458
9. Nakamura, F., Osborn, T. M., Hartemink, C. A., Hartwig, J. H., and Stossel, T. P. (2007) J. Cell Biol. 179, 1011–1025
10. Heikkinen, O. K., Ruskamo, S., Konarev, P. V., Svergun, D. I., Iivanainen, T., Heikkinen, S. M., Permi, P., Koskela, H., Kipeläinen, I., and Yla¨nne, J. (2009) J. Biol. Chem. 284, 25450–25458
11. Lad, Y., Kiema, T., Jiang, P., Pentikäinen, O. T., Coles, C. H., Campbell, I. D., Calderwood, D. A., and Yla¨nne, J. (2007) EMBO J. 26, 3993–4004
12. van der Flier, A., Kuikman, I., Kramer, D., Geerts, D., Kreft, M., Takafuta, T., Shapiro, S. S., and Sonnenberg, A. (2002) J. Cell Biol. 156, 361–376
13. Kiema, T., Lad, Y., Jiang, P., Oxley, C. L., Baldassarre, M., Wegener, K. L., Campbell, I. D., Yla¨nne, J., and Calderwood, D. A. (2006) Mol. Cell 21, 337–347
14. Takala, H., Nurminen, E., Nurmi, S. M., Aatonen, M., Strandin, T., Takatalo, M., Kiema, T., Gahrnberg, C. G., Yla¨nne, J., and Fagerholm, S. C. (2008) Blood 112, 1853–1862
15. Lad, Y., Jiang, P., Ruskamo, S., Harburger, D. S., Yla¨nne, J., Campbell, I. D., and Calderwood, D. A. (2008) J. Biol. Chem. 283, 35154–35163
16. Ithychanda, S. S., Das, M., Ma, Y. Q., Ding, K., Wang, X., Gupta, S., Wu, C., Plow, E. F., and Qin, J. (2009) J. Biol. Chem. 284, 4713–4722
17. Chen, H. S., Kolahi, K. S., and Mofrad, M. R. K. (2009) Biophys. J. 97, 3095–3104
18. Pentikäinen, U., and Yla¨nne, J. (2009) J. Mol. Biol. 393, 644–657
19. Xu, W., Xie, Z., Chung, D. W., and Davie, E. W. (1998) Blood 92, 1268–1276
20. Xie, Z., Xu, W., Davie, E. W., and Chung, D. W. (1998) Biochem. Biophys. Res. Commun. 251, 914–919
21. Jiang, P., and Campbell, I. D. (2008) Biochemistry 47, 11055–11061
22. Delaglio, F., Grzesiek, S., Vuister, G. W., Zhu, G., Pfeifer, I., and Bax, A. (1995) J. Biomol. NMR 6, 277–293
23. Laemmli, U. K. (1970) Nature 227, 680–685
24. Matsudaera, P. (1987) J. Biol. Chem. 262, 10035–10038
25. Roessle, M. W., Klaering, R., Ristau, U., Robrah, B., Jahn, D., Gehrmann, T., Konarev, P., Round, A., Fiedler, S., Hermes, C., and Svergun, D. (2007) J. Appl. Crystallogr. 40, S190–194
26. Svergun, D. I. (1992) J. Appl. Crystallogr. 25, 495–503
27. Bernadó, P., Mylonas, E., Petoukhov, M. V., Blackledge, M., and Svergun, D. I. (2007) J. Am. Chem. Soc. 129, 5656–5664
28. Volkov, V. V., and Svergun, D. I. (2003) J. Appl. Crystallogr. 36, 860–864
29. Petoukhov, M. V., and Svergun, D. I. (2005) Biophys. J. 89, 1237–1250
30. Wriggers, W. (2010) Biophys. Rev. 2, 21–27
31. Humphrey, W., Dalke, A., and Schulten, K. (1996) J. Mol. Graph. 14, 33–38, 27–28
32. Merritt, E. A., and Bacon, D. I. (1997) Methods Enzymol. 277, 505–524
33. Pantoliano, M. W., Petrella, E. C., Kwasnoski, J. D., Lobanov, V. S., Myslik, J., Graf, E., Carver, T., Asel, E., Springer, B. A., Lane, P., and Salemme, F. R. (2001) J. Mol. Screen. 6, 429–440
34. Svergun, D. I., Petoukhov, M. V., and Koch, M. H. (2001) Biophys. J. 80, 2946–2953
35. Ithychanda, S. S., Hsu, D., Li, H., Yan, L., Liu, D. D., Liu, D., Das, M., Plow, E. F., and Qin, J. (2009) J. Biol. Chem. 284, 35113–35121
36. Wright, P. E., and Dyson, H. J. (1999) J. Mol. Biol. 293, 321–331
37. Demchenko, A. P. (2001) J. Mol. Recognit. 14, 42–61
38. Dyson, H. J., and Wright, P. E. (2002) Curr. Opin. Struct. Biol. 12, 54–60
39. Moik, D. V., Janbandhu, V. C., and Fässler, R. (2011) J. Cell Sci. 124, 414–421
40. Dunker, A. K., Lawson, J. D., Brown, C. J., Williams, R. M., Romero, P., Oh, I. S., Oldfield, C. J., Campen, A. M., Ratliff, C. M., Hips, K. W., Auilio, J. Nissen, M. S., Reeves, R., Kang, C., Kissinger, C. R., Bailey, R. W., Griswold, M. D., Chiu, W., Garner, E. C., and Oboladzic, Z. (2001) J. Mol. Graph. Model. 19, 26–59
41. Uversky, V. N. (2002) Protein Sci. 11, 739–756
42. Uversky, V. N. (2002) Eur. J. Biochem. 269, 2–12
43. Konarev, P. V., Volkov, V. V., Sokolova, A. V., Koch, M. H. J., and Svergun, D. I. (2003) J. Appl. Cryst. 36, 1277–1282